Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 71.4% during trading on Tuesday . The stock traded as high as C$0.12 and last traded at C$0.12. 592,088 shares were traded during trading, an increase of 516% from the average session volume of 96,162 shares. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The business’s 50 day moving average is C$0.08 and its two-hundred day moving average is C$0.07. The firm has a market capitalization of C$9.15 million, a PE ratio of -5.25 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- 3 Fintech Stocks With Good 2021 Prospects
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
- Short Selling: How to Short a Stock
- These 3 Retail Stocks Can Keep Winning in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
